Claire Lafay-Chebassier

7PUBLICATIONS
30CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyLearning, motivation and emotionPharmacogenomicsEpidemiological methods
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Nov 07, 2025
Respiratory Disorders Associated with Antibody-Drug Conjugates: A Combined Analysis of the French and the WHO Pharmacovigilance Databases.

Victor Mirleau, Alex Hlavaty, Etienne-Marie Jutant

|Aug 30, 2025
Efficacy and Safety of NFL-101 as a Smoking Cessation Therapy: A Randomized Phase II Clinical Trial CESTO2.

Claire Lafay-Chebassier, Pierre-Olivier Girodet, Fabrice Laine

|Nov 25, 2024
French-Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Clinical Use of Mavacamten.

Louis Lebreton, Jean-Christophe Boyer, Claire Lafay-Chebassier

|May 29, 2024
Smokers with higher positive or negative urgency have lower rates of smoking cessation success 12 months after a quit attempt.

Paul Brunault, Isabelle Ingrand, Marcello Solinas

|Jul 27, 2021
Impact of brain-derived neurotrophic factor Val66Met polymorphism and response to escitalopram or paroxetine in obsessive-compulsive disorder.

Ghina Harika-Germaneau, Nicolas Langbour, Sylvie Patri

|Sep 22, 2020
Effectiveness of drugs acting on adrenergic receptors in the treatment for tobacco or alcohol use disorders: systematic review and meta-analysis.

Paul Vanderkam, Marcello Solinas, Isabelle Ingrand

Pageof 2

Frequent Collaborators

1 joint publications

Isabelle Ingrand

1 joint publications

Gautier Defossez

1 joint publications

Aurélie Ferru

1 joint publications

Pierre Ingrand